1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Choroidal Neovascularization Market 2016-2020

Global Choroidal Neovascularization Market 2016-2020

  • February 2016
  • -
  • Infiniti Research Limited
  • -
  • 56 pages

About Choroidal Neovascularization

Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).

Technavio’s analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- Bayer HealthCare
- Novartis
- Regeneron Pharmaceuticals
- F. Hoffmann-La Roche


Other prominent vendors
- Alcon
- Allergan
- Avalanche
- Bausch and Lomb
- Gilead Sciences
- Iconic Therapeutics
- Lpath
- Neurotech Pharmaceuticals
- Ohr Pharmaceutical
- Opthea
- Ophthotech
- PanOptica
- Pfizer
- Promedior
- QLT
- Quark
- Resolvyx Pharmaceuticals
- RXi Pharmaceuticals
- Sagent Pharmaceuticals
- Santen
- Sanwa Kagaku Kenkyusho

Market driver
- Growing older population
- For a full, detailed list, view our report

Market challenge
- High cost of treatment
- For a full, detailed list, view our report

Market trend
- Strategic alliances and M&A
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Choroidal Neovascularization Market 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
- Key buying criteria
PART 05: Disease overview
- Introduction
- Pathophysiology
- Symptoms
- Management
- Epidemiology
PART 06: Product portfolio of approved therapies
PART 07: Pipeline analysis
- OHR-102
- RTH258
- Fovista
- RG7716
- PF-04523655
- NT-503
- LFG316
- REGN2176-3
- Zimura
- LHA510
- DE-120
PART 08: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 09: Market segmentation by ROA
- IV
- Intravitreal
PART 10: Geographical segmentation
- Global choroidal neovascularization market by geographical segmentation 2015-2020
- Choroidal neovascularization market in Americas
- Choroidal neovascularization market in EMEA
- Choroidal neovascularization market in APAC
PART 11: Market drivers
- Growing older population
- Increased prevalence of chronic diseases
- High patient and physician satisfaction
- Increase in diagnosis rate
PART 12: Impact of drivers
PART 13: Market challenges
- High cost of treatment
- Limited public awareness
- Side effects associated with treatment options
- Availability of alternative therapies
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Strategic alliances and MandA
- Increased initiatives and programs
- Use of combination therapies
- Increase in RandD
PART 16: Vendor landscape
- Competitive scenario
- Market analysis 2015
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
- Bayer HealthCare
- Other prominent vendors
PART 17: Appendix
- List of abbreviations
PART 18: Explore Technavio



List of Exhibits
Exhibit 01: Product offerings 7
Exhibit 02: Key buying criteria for choroidal neovascularization drugs
Exhibit 03: Types of choroidal neovascularization
Exhibit 04: Symptoms of choroidal neovascularization
Exhibit 05: Treatment options for choroidal neovascularization
Exhibit 06: Pipeline portfolio: Global choroidal neovascularization therapeutics
Exhibit 07: Global choroidal neovascularization market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global choroidal neovascularization market by ROA 2015
Exhibit 10: Market segmentation by geography 2015
Exhibit 11: Choroid neovascularization market revenue by geography 2015-2020 ($ billions)
Exhibit 12: Choroidal neovascularization market in Americas 2015-2020 ($ billions)
Exhibit 13: Choroidal neovascularization market in EMEA 2015-2020 ($ billions)
Exhibit 14: Choroidal neovascularization market in APAC 2015-2020 ($ millions)
Exhibit 15: Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Vendor ranking of global choroidal neovascularization market 2015
Exhibit 19: Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions)
Exhibit 20: Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions)
Exhibit 21: Roche: Key takeaways
Exhibit 22: Novartis' specialty ophthalmic segmentation by revenue 2014
Exhibit 23: Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions)
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions)
Exhibit 26: Regeneron Pharmaceuticals: Key takeaways
Exhibit 27: Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions)
Exhibit 28: Bayer HealthCare: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.